Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2017

Published: Aug, 2017 | Pages: 136 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape.

Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 3, 1, 23, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Peripheral Neuropathy - Overview
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development
Achelios Therapeutics Inc
Advinus Therapeutics Ltd
Apollo Endosurgery Inc
Aptinyx Inc
Asahi Kasei Pharma Corp
Can-Fite BioPharma Ltd
Celgene Corp
Eisai Co Ltd
Immune Pharmaceuticals Inc
Insys Therapeutics Inc
Kineta Inc
KPI Therapeutics Inc
Krenitsky Pharmaceuticals Inc
Midatech Pharma US Inc
Mundipharma International Ltd
Nemus Bioscience Inc
Neurocentrx Pharma Ltd
Panacea Pharmaceuticals Inc
PeriphaGen Inc
PledPharma AB
Sova Pharmaceuticals Inc
Trevena Inc
WEX Pharmaceuticals Inc
Chemotherapy Induced Peripheral Neuropathy - Drug Profiles
(amitriptyline + ketamine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-1083 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-1710 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-2009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-3330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BR-297 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dimiracetam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Chemotherapy Induced Peripheral Neuropathy and Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Peripheral Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DX-0332 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-2072 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KCP-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ketoprofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-544 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KRN-5500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-11A31BHS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lpathomab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MR-309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-2111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-2222 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NRX-2922 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-24336 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAN-811 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PGN-503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piclidenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pirenzepine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-095 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Q-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ricolinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Cystathionine Gamma Lyase for Inflammatory Pain and Chemotherapy Induced Peripheral Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block Nav 1.8 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target S1PR for Central Nervous System and Toxicology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tetrodotoxin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
thrombomodulin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
U-2902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XT-150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZF-198 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products
Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones
Featured News & Press Releases
Aug 02, 2017: Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference
Jul 13, 2017: Apexian Pharmaceuticals Announces FDA Agreement For Inclusion of Chemotherapy Induced Peripheral Neuropathy (CIPN) Indication Under Currently Approved IND
Jun 29, 2017: PledPharma strengthens the management team with a Vice President Product Strategy and Development
Mar 08, 2017: Regenacy Pharmaceuticals Demonstrates Reversal of Chemotherapy-Induced Peripheral Neuropathy with HDAC6 Inhibitor Ricolinostat in Preclinical Model
Dec 01, 2016: Nemus Bioscience Announces Milestones In The Development Of Fully Synthetic Clinical-Grade Active Pharmaceutical Ingredient For Drug Candidate NB2111 And Formulation Contract With AMRI And Catalent Pharma Solutions
Jun 02, 2016: NEMUS Bioscience Identifies Unique Cannabidiol Derivative as a Lead Candidate in Its Neuropathy-Related Pain Management Program
May 19, 2016: PledPharma to present the Phase IIb PLIANT study data at ASCO 2016
May 17, 2015: Wex Pharmaceuticals Announces Presentation Of Preclinical Data On Chemotherapy-Induced Peripheral Neuropathy And Burn Injury Pain At The 2015 American Pain Society Conference On Its Lead Compound, Halneuron (TTX)
Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA
Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program
Apr 10, 2012: EpiCept's AmiKet Receives Fast Track Designation From FDA
Feb 07, 2012: EpiCept Files For AmiKet Fast Track Designation
Dec 23, 2011: EpiCept Receives FDA Permission To Initiate AmiKet Phase III Clinical Development
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Advinus Therapeutics Ltd, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Apollo Endosurgery Inc, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aptinyx Inc, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Asahi Kasei Pharma Corp, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Can-Fite BioPharma Ltd, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Celgene Corp, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Eisai Co Ltd, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Insys Therapeutics Inc, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kineta Inc, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by KPI Therapeutics Inc, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Krenitsky Pharmaceuticals Inc, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Midatech Pharma US Inc, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mundipharma International Ltd, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Nemus Bioscience Inc, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Neurocentrx Pharma Ltd, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Panacea Pharmaceuticals Inc, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by PeriphaGen Inc, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by PledPharma AB, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sova Pharmaceuticals Inc, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Trevena Inc, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by WEX Pharmaceuticals Inc, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H2 2017
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H2 2017 (Contd..1), H2 2017
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H2 2017